AQST has been the subject of a number of other research reports. BMO Capital Markets assumed coverage on shares of Aquestive Therapeutics in a research note on Monday, August 20th. They issued an outperform rating for the company. Royal Bank of Canada assumed coverage on shares of Aquestive Therapeutics in a research note on Monday, August 20th. They issued an outperform rating and a $23.00 price target for the company. Finally, JMP Securities assumed coverage on shares of Aquestive Therapeutics in a research note on Monday, August 20th. They issued an outperform rating and a $29.00 price target for the company.
Shares of NASDAQ:AQST opened at $14.90 on Wednesday. The company has a debt-to-equity ratio of -1.16, a current ratio of 1.14 and a quick ratio of 0.95. Aquestive Therapeutics has a 12-month low of $13.61 and a 12-month high of $20.70.
Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, September 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($1.66). The company had revenue of $13.93 million for the quarter. On average, sell-side analysts predict that Aquestive Therapeutics will post -0.93 EPS for the current year.
In related news, Director Douglas K. Bratton purchased 165,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 24th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $2,475,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Recommended Story: Analyst Ratings
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.